Sangamo Therapeutics Bolsa (NASDAQ: SGMO)

Sangamo Therapeutics

SANGAMO THERAPEUTICS INC

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Movers_Stocks

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADPT

CXAI

ENTO

HRTG

IIIN

LION

LSAK

MLNK

MULN

OLMA

RNAC

SGMO

SHCO

SLSR

Sangamo Therapeutics se dispara tras anunciar un acuerdo exclusivo con Eli Lilly sobre tecnología genética patentada. ¿Qué implica esto?

Acciones de Sangamo Therapeutics (SGMO) se disparan un 40%; Aquí están 20 acciones que se mueven en premercado

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

NMTC

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: AMS, GES, NMTC, SLP y SGMO.

5 acciones en el foco este viernes: AMS, GES, NMTC, SLP y SGMO

Nvidia, Moderna, Lucid, Dominari Holdings, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Equities

FIVE

TSLA

El mercado bursátil estadounidense se desplomó; descubre qué acciones sufrieron más y por qué cayeron tan fuerte.

RH, Five Below, Sangamo, Bank Of America, Tesla: 5 acciones que están en el radar de los inversores

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics Inc

Press Releases

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

Biotech

General

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Health Care

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Crescent Biopharma

Compugen

Coherus Oncology

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Fate Therapeutics

Forte Biosciences

Fennec Pharmaceuticals Inc. - Common Stock

Fennec Pharmaceuticals

Genfit

Genelux

Heron Therapeutics

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Palisade Bio

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Pyxis Oncology

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Vor Biopharma

Zura Bio Limited - Class A Ordinary shares

Zura Bio

HC Wainwright & Co.

Barclays

RBC Capital

Truist Securities

Comments

Sangamo Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL